We studied the effects of angiotensin II during low-flow ischemia and reperfusion using red cell-perfused isovolumic rabbit hearts. Under baseline conditions where coronary perfusion pressure (CPP) was 100 mm Hg and left ventricular end-diastolic pressure (LVEDP) was set at 10 mm Hg, 10-8 M angiotensin II caused a mild increase in LV developed pressure (+12%) and decrease in coronary flow (-8%). Low-flow ischemia was imposed by reducing CPP to 15 mm Hg for 30 min followed by 30 min of reperfusion. During ischemia, the angiotensin II group showed a gradual further reduction in coronary flow in association with a greater depression of LV developed pressure and increase in LVEDP relative to the no-drug group. To separate the effect of angiotensin II on coronary flow from a direct myocardial effect, the angiotensin II group was compared with an additional no-drug group with a matched progressive reduction in coronary flow during ischemia. In these groups, the ischemic depression of LV developed pressure, myocardial ATP levels, and lactate production were similar. However, the ischemic rise in LVEDP was greater (42.0±5.4 vs. 19.9±1.3 mm Hg, P < 0.01) and recovery was incomplete in the angiotensin II group. These observations suggest that angiotensin II exerts a direct adverse effect on LV diastolic relaxation during low-flow ischemia and recovery. (J. Clin. Invest. 1992. 89:490-498.) 
Introduction
Transient myocardial ischemia in patients with coronary artery disease is associated with a severe and reversible depression of myocardial relaxation and elevation of left ventricular enddiastolic pressure (LVEDP) (1) (2) (3) . ' We have previously shown that these acute and reversible changes in diastolic function can 1. Abbreviations used in this paper: ACE, angiotensin-converting enzyme; CP, creatine phosphate; CPP, coronary perfusion pressure; LVEDP, left ventricular end-diastolic pressure.
be simulated in isolated red cell-perfused hearts in which the critical feature is that ischemia is imposed by imposition of a preserved but greatly reduced level of coronary flow, sufficient to sustain systolic force development, in contrast with primary no-flow ischemia which results in immediate cessation of contractile function, loss ofall coronary turgor, and an early downward shift in the LV diastolic pressure-volume relation (4) (5) (6) . These acute and reversible changes in relaxation and diastolic function during low-flow ischemia and during hypoxia are postulated to be related in part to myocardial ATP depletion in association with the reversible elevation ofcytosolic Ca2l (7, 8) .
Consistent with these postulated mechanisms, the rapid and reversible changes in relaxation and diastolic distensibility that occur during low-flow ischemia are exacerbated by interventions which increase Ca2" availability and myocardial energy demand (4, 5) and are more pronounced in hypertrophied hearts with intrinsic impairment of cytosolic Ca2" handling (9-1 1).
However, the potential contribution ofthe renin-angiotensin system to the physiologic and metabolic response of the heart to low-flow ischemia has received little attention. In this regard, there is substantial evidence which supports the presence of an endogenous renin-angiotensin system in the heart (12) (13) (14) . Experiments in isolated perfused hearts by Lindpaintner et al. (15) and from our laboratories (16) have demonstrated the intracardiac activation ofangiotensin I to II, and we have recently shown that angiotensin-converting enzyme (ACE) mRNA is expressed in the heart (16) . Under well-oxygenated conditions, the physiologic action of angiotensin II on the heart may include local effects on cardiac contractility and coronary vasomotor tone as well as a role in modulating cell growth (12, (15) (16) (17) . However, there is indirect evidence that the availability of angiotensin II to the heart during ischemia may be deleterious. Recent studies have suggested that specific inhibition of angiotensin II activation has the potential to protect against ischemia and reperfusion injury (18) (19) (20) . However, the effects of angiotensin II on myocardial contractility and relaxation, coronary vasomotor tone, and metabolism during low-flow ischemia are not known.
To test the hypotheses that angiotensin II directly impairs the preservation of contractile function during low-flow ischemia and exacerbates myocardial stunning during reperfusion, we compared the effects of 30 min of low-flow ischemia and reperfusion on coronary vasoreactivity, systolic and diastolic function, and myocardial lactate production in isolated isovolumic red cell-perfused rabbit hearts perfused with I0-' M angiotensin II in comparison with control hearts without drug. Myocardial ATP and creatine phosphate levels were measured in additional hearts at end-ischemia. Our experiments demon-strated that angiotensin II directly impaired LV ventricular diastolic relaxation during ischemia and its recovery independent of its effects on coronary vascular tone and systolic function or the magnitude of high energy phosphate depletion.
Methods
Experimental preparation. We used an isolated isovolumic red cellperfused rabbit heart preparation that has been developed in our laboratory and has been described previously in detail (4) (5) (6) . Male, albino New Zealand rabbits (1.3-2.2 kg) were heparinized (1,000 U, intravenously) and anesthetized with sodium pentobarbital (50 mg/kg, intravenously). After thoracotomy, the heart was isolated, a short perfusion cannula was inserted into the ascending aortic stump and positioned immediately above the aortic valve, and the coronary arteries were perfused via the aortic root with the red cell-containing perfusate. The interval between isolation ofthe heart and initiation ofcoronary perfusion in all experiments was < 15 s.
A bovine red cell perfusate was used which was developed by Marshall and Zhang (21) and in our laboratory (6 After initiation of coronary perfusion, an apical drainage cannula was inserted into the apex ofthe left ventricle to remove any Thebesian drainage. The cavae were ligated and a cannula was inserted via the ligated pulmonary artery into the right ventricle to collect the coronary venous effluent and completely empty the right ventricle. A pacing electrode connected to a stimulator (Grass Instrument, Co., Quincy, MA) and a thermistor (Yellow Springs Instrument, Co., Yellow Springs, OH) were inserted into the right ventricle via the right atrium. Myocardial temperature was maintained at 37°C and heart rate was maintained at a physiological rate of 3 Hz by electrical pacing. A collapsed thin-walled latex balloon was placed in the left ventricle via the left atrium. The balloon was large enough so that no measurable pressure was generated by the balloon itself over the range of LV volume used in this experiment. The heart was then placed in a water-jacketed constant temperature chamber.
The perfusion system consisted of a "venous" reservoir, a variableflow pump, an oxygenator, a water-jacketed "arterial" reservoir, and a filter of 20-,um pore size. In this system, the arterial reservoir was pressurized, and coronary perfusion pressure (CPP) was controlled by a valve that adjusted the pressure of the reservoir. Coronary flow was allowed to vary and thus depend on coronary vasomotor autoregulation.
Measurements. Coronary perfusion pressure, LV pressure and its first derivative were recorded continuously on a multichannel physiologic recorder (Gould, Inc., Cleveland, OH). CPP was monitored via a sidearm of the aortic cannula connected to a pressure transducer (Statham model P23Db, Gould, Inc.). LV pressure was measured with short, stiff fluid-filled polyethylene tubing attached to a model P23Db pressure transducer. The frequency response and damping characteristics of this system have been described from this laboratory (22) At the end of the experiment, hearts were removed from aortic cannula. After atria and great vessels were removed, total heart and LV weights were measured. The left ventricle was oven-dried for 2 wk for calculation of the LV wet/dry weight ratio.
Protocol II: comparison ofhearts with angiotensin II vs. no drug at matched levels of progressive coronary flow reduction. As shown in Results, angiotensin II caused a gradual progressive fall of coronary flow during ischemia compared with the control group with no drug. To distinguish any direct effect of angiotensin II on myocardial function and the effects on coronary flow, another protocol was added. In this protocol (n = 10, control hearts with no drug), coronary flow was gradually decreased during low-flow ischemia in order to simulate the change in coronary flow that had occurred in the angiotensin group. To simulate the gradual decrease in coronary flow seen in the angiotensin group, CPP was initially reduced to 15 mm Hg and coronary flow was then decreased by a step-wise reduction ofcoronary perfusion pressure by 1-1.5 mmHg every 5 min (progressive ischemia group, n = 10). In this progressive ischemia group, the stepwise reduction in CPP was associated with CPP levels of 15±0.2, 13.7±0.3, 12.4±0.3, 11.2±0.6, 10.5±0.6, and 10. 1±0.8 mm Hg. After progressive low-flow ischemia, hearts were reperfused for 30 min as in protocol I.
Protocol III: effects ofangiotensin II in the absence ofischemia. To evaluate the effects of angiotensin II alone for the duration of the ischemia-reperfusion protocols described above, four hearts were perfused at a CPP of 100 mm Hg with angiotensin II for 70 min, which is equal to the duration ofangiotensin exposure in the ischemia and reperfusion protocols cited above.
Analysis ofmyocardial adenosine triphosphate (A TP) and creatine phosphate (CP) contents. Myocardial ATP and CP contents were determined in three additional groups of hearts (n = 5 each) at the end of a 30-min period of low-flow ischemia following the protocols described above: a control group which received no drug (n = 5), an angiotensin group which received angiotensin II infusion (n = 5), and a progressive ischemia group which received no drug as well as the gradual reduction ofcoronary flow during ischemia to simulate the reduction ofcoronary flow observed in the angiotensin group (n = 5).
At the end of the 30-min period of low-flow ischemia during continued perfusion, the heart was quickly trimmed of atria and right ventricular free wall, and the LV was rapidly frozen with Wollenberger aluminum clamps cooled with liquid nitrogen. Each frozen sample was rapidly weighed and pulverized in a mortar in liquid nitrogen. An aliquot of the frozen powder was weighed and then heated (370C) in an oven for 48 h to determine the frozen/dry weight ratio. The remainder of the sample was mixed with 0.6 N perchloric acid, homogenized, centrifuged, and neutralized with 5 mol/liter potassium carbonate. The aliquot of neutralized homogenate were placed in preweighed reagent vials and analyzed for ATP by methods of Adams (25) . CP was measured by the methods of Altschuld et al. (26) by adding an excess of creatine kinase to the ATP reaction mixture after ATP assay had reached completion. Measurements are expressed as micromoles per gram LV dry weight. In our laboratory, basal values for age-matched New Zealand rabbits are: ATP, 24.1±0.7 gmol/g LV dry weight, and CP, 49.8±0.5 gmol/g LV dry weight.
Statistical analysis. All data are presented as the mean±SEM.-For each protocol, statistical comparisons between groups at baseline and at preischemia were done using analysis of variance. Comparison between groups in response to 30-min low-flow ischemia and in response to 30-min reperfusion were performed using analysis of variance (AN-OVA) for repeated measures. Baseline measurements and 30-min ischemic metabolic measurements (ATP, CP) between two groups were tested by the Student's t test for unpaired data. A P value of < 0.05 was accepted as the level of significance.
Results
Effects ofangiotensin II in absence of ischdmia (Table I) . At baseline, there were no differences in LV hemodynamic parameters or coronary flow between the groups. In response to the preischemic 10-min infusion ofangiotensin II, there was a mild positive inotropic effect (12% increase in LV developed pressure and 19% increase in LV + dP/dt) with a slight fall in LVEDP and no difference in LV -dP/dt in the angiotensin II group compared with the control group. The positive inotropic effect was evident at 3 min and reached its maximal effect at 6 min of angiotensin II perfusion with no further changes. Compared with baseline values, there was a slight (8%) fall in coronary flow in the angiotensin group, but there was no significant difference in coronary flow or aerobic myocardial lactate extraction between the angiotensin II group and the control group before ischemia.
Effects ofangiotensin II during low-flow ischemia and reperfusion (Table I) . Both groups showed an immediate fall in LV developed pressure with the onset oflow-flow ischemia. LV developed pressure subsequently remained stable in the control group whereas it decreased gradually in the angiotensin II group (Fig. 1, left) . At the end ofthe 30-min period oflow-flow ischemia, LV developed pressure and LV + dP/dt were significantly lower in the angiotensin II group compared with the no-drug control group (Table I) . During low-flow ischemia, there was also a marked progressive rise in LVEDP in the angiotensin group compared with the control group (42.0±5.4 vs. 13 .5±1.5 mm Hg, P < 0.01) in association with greater depression of LV + dP/dt. During the first 5 min oflow-flow ischemia at a constant CPP of 15 mm Hg, the level of reduced coronary flow was similar in both groups, but coronary flow then progressively decreased in the angiotensin II group. In contrast, the level of coronary flow remained stable during the entire period of ischemia in the control group. Myocardial lactate production as reported by washout during reperfusion was higher in the angiotensin II group (Fig. 2, upper panel) .
During the 30 min ofreperfusion imposed by restoring CPP to 100 mm Hg (Fig. 1, right) , there were no differences in the magnitude of initial reactive hyperemia and subsequent levels of coronary flow at 30 min of reperfusion. The LV developed pressure recovered to -73% of baseline in the control group and to 62% of baseline in the angiotensin II group at end of the 30-min reperfusion period. In the control group, there was immediate recovery of the ischemic elevation of LVEDP to baseline, whereas recovery ofelevated LVEDP in the angiotensin II group was prolonged.
Comparison of hearts with angiotensin II vs. no drug at matched levels ofischemic coronaryflow (Table II) . To discriminate the direct effects ofangiotensin II on myocardial function from its depressant effects on coronary flow, the angiotensin II group was compared with an additional group ofcontrol hearts (progressive ischemia group) in which coronary flow was gradually decreased during the 30-min period of ischemia to simulate the change in coronary flow observed in the angiotensin II group. In this protocol, coronary flow during ischemia (Fig. 3 , left) and myocardial lactate production ( Fig. 2) were comparable in both groups. Both groups showed a progressive fall in LV developed pressure (Fig. 3, left) and LV + dP/dt to similar levels at the end of 30 min of ischemia. In contrast, despite the presence of matched levels of coronary flow throughout the 30-min period of ischemia, the increase in isovolumic LVEDP occurred earlier and was greater in the angiotensin II group compared with the progressive ischemia group (Fig. 3, left) . During reperfusion, the recovery of LV diastolic pressure to baseline was slower and incomplete in the angiotensin II group compared with the progressive ischemia group (Fig. 3, right) . At the end of the 30-min period of reperfusion, the recovery of LV developed pressure was less complete and recovery of LV + dP/dt was similar in the angiotensin II group compared with the progressive ischemia group. There were no differences in the LV wet/dry weight ratio between the groups.
Effects of angiotensin II without ischemia. To exclude an adverse effect of prolonged angiotensin II perfusion on diastolic function in the absence of ischemia, an additional four hearts were perfused at a CPP of 100 mm Hg with 10-8 M angiotensin II for 70 min, the total duration of angiotensin II perfusion in the ischemia-reperfusion protocols cited above. Angiotensin II perfusion was associated with a mild inotropic effect similar to that described above. During 70 min of angiotensin II perfusion in the absence of ischemia, there was no significant change in LVEDP (9.8±0.3 to 7.5±0.6 mm Hg, NS) or LV -dP/dt (from 1,145±69 to 1,143±142 mm Hg/s, NS).
Myocardial ATP and CP levels at end-ischemia. LV myocardial ATP and CP content were measured at the end of 30 min of low-flow ischemia at CPP of 15 mm Hg without reperfusion in five additional hearts in each of the three groups: the control group with no drug, the angiotensin II group, and the progressive ischemia group (hearts with no drug in which coronary flow was progressively reduced during the ischemic period to match levels observed in the angiotensin II group).
Within each group, the measurements of LV function and coronary flow at baseline and in response to low-flow ischemia were similar to those observed in hearts exposed to both ischemia and reperfusion. At the end of 30 min of low-flow isch- tinued but severely restricted coronary flow, a reduced level of contractile function is preserved whereas impaired diastolic relaxation and the elevation of diastolic pressure occur rapidly. We have previously shown that these acute and reversible changes in diastolic function can be simulated in the isolated red cell-perfused heart model used in this experiment in which the critical feature is that global ischemia is produced at a reduced level of coronary blood flow sufficient to sustain contractile function (4-6). The acute and reversible changes in diastolic function characteristic of low-flow ischemia are postulated to be related to modest levels of high-energy phosphate depletion in association with the impaired restoration of normal diastolic intracellular calcium levels (7, 8, 27) . Consistent with this view, the changes in diastolic relaxation and distensibility that occur during low-flow ischemia are modified by interventions which alter calcium availability or energy demand and availability (4-6, 28) and amplified in hypertrophied hearts with intrinsic impairment of calcium homeostasis (10, 11) .
However, the potential contribution of neurohumoral factors, such as the renin-angiotensin system, on the contractile and metabolic response of the heart to low-flow ischemia has received little attention. This is of interest since there is evidence that angiotensin II (12, 15, 16, 30, 31) . In contrast, there is indirect evidence that suggests deleterious effects of angiotensin II on the heart subjected to ischemia and reperfusion. Recent studies have shown the beneficial effect ofthe specific inhibition ofACE and angiotensin II activation against ischemic and reperfusion injury (18, 19, 20, 32) . To study the direct effects ofangiotensin II on myocardial contractile function and metabolism during ischemia and reperfusion, we compared the effects of 30 min of low-flow ischemia and reperfusion in beating, isovolumic red cell-perfused rabbit hearts in the presence and absence of 10-8 M angiotensin II. Our new observations indicate that angiotensin II directly impairs LV diastolic function during low-flow ischemia and its recovery during reperfusion, independent of the depressant ef- fects of angiotensin II on coronary vasomotor tone during ischemia and the magnitude of high-energy phosphate depletion.
Effects of angiotensin II in nonischemic isolated hearts.
Under well-oxygenated conditions, we perfused isolated paced red cell-perfused rabbit hearts with a concentration of angiotensin II which produced a mild positive inotropic effect, no adverse effect on diastolic function, and minimal coronary vasoconstriction in the presence of a normal aerobic pattern of lactate metabolism. Angiotensin II's constricting effect on vasomotor tone has been observed in all species studied to date, whereas the positive inotropic effect of angiotensin II that we observed is consistent with previous studies in the rabbit, chick, dog, and cat (12, (33) (34) (35) (36) and humans (17) . It is noteworthy and not well understood that angiotensin II causes a negligible or depressant inotropic effect in some species such as the rat and guinea pig (15, 16, 30, 37) . This contrasts with the positive inotropic and lusitropic effects of f3-adrenergic agonists observed across species and suggests that the physiologic effects of angiotensin II are not predominantly mediated by cyclic AMPdependent pathways (30) . Effects of angiotensin II during low-flow ischemia and reperfusion. The imposition of ischemia imposed by reducing coronary perfusion pressure from 100 to 15 mm Hg was immediately followed by a reduction in coronary flow to a level of 20% ofbaseline and a reduction in parameters ofcontractile function to 25% ofbaseline at 1 min ofischemia. Consistent with prior studies using this model of transient low-flow ischemia (4, 5, 1 1) , coronary flow and all parameters of systolic function remained stable during the remainder of the 30 Abbreviations: PI group, progressive ischemia group consisting of control hearts with no drug in which coronary flow was progressively reduced during the 30-min period of ischemia to match levels in the AT group; AT group, hearts perfused with angiotensin II which was begun 10 min preischemia and continued throughout ischemia and reperfusion. Other terms, same as Table 1. period of ischemia in the control hearts with no drug. In contrast, the hearts perfused with angiotensin II showed a gradual progressive fall in coronary flow during ischemia in association with greater myocardial lactate production and washout. During reperfusion, the magnitude of reactive hyperemia and level of coronary flow at 30 min of recovery were similar in both groups. These observations suggest that a level ofangiotensin II that caused minimal changes in coronary vasomotor tone under oxygenated conditions promoted inappropriate coronary vasoconstriction and exacerbation of the magnitude of ischemia in the setting of a reduced coronary perfusion pressure. In the hearts perfused with angiotensin II compared with control hearts, a positive inotropic effect was no longer evident at 1 min of ischemia and this group showed a progressive depression of contractile function during low-flow ischemia. During reperfusion, recovery of systolic function was slower and incomplete in the angiotensin group compared with the control groups. These results contrast with prior experiments from our laboratory which showed that isoproterenol infusion at a dose that caused a comparable mild inotropic effect under oxygenated conditions was associated with a favorable effect on both systolic and diastolic function during low-flow ischemia (5). During 30 min of low-flow ischemia, angiotensin II caused a more rapid and severe increase in isovolumic LVEDP of 30 mm Hg in association with a greater depression of LV -dP/dt, and very delayed recovery during reperfusion in comparison with control hearts with no drug. This deleterious effect of angiotensin II on diastolic function in the angiotensin II group is unlikely to be explained by exaggerated energy demand in that heart rate was constant and parameters of contractile function were lower during ischemia in the angiotensin group relative to the control group, nor can it be explained by the extrinsic factors of coronary turgor or edema since coronary flow was lower and the wet/dry ratio was similar in the angiotensin group compared with control hearts.
Comparison of the effects of angiotensin II vs. no drug at matched levels of ischemic coronaryflow. To distinguish any direct myocardial effect ofangiotensin II on LV contractile and lusitropic function from its depressant effects on coronary flow during low-flow ischemia, an additional group ofcontrol hearts with no drug was studied in which coronary flow was progressively reduced during the 30-min period of ischemia. With this experimental strategy, coronary flow throughout the 30-min period of ischemia was similar in both groups. Although differences in subendocardial flow cannot be excluded, myocardial lactate production and washout were virtually identical in the angiotensin II group and this control group with progressive ischemia. At matched levels of progressive reduction of coronary flow, there was now a similar magnitude of depression of LV developed pressure in response to 30 min ofischemia. However, during ischemia, angiotensin II compared with no drug caused a more rapid and severe elevation of isovolumic LVEDP whose recovery was slower and incomplete during the 30-min period of reperfusion.
Analysis of left ventricular myocardial high energy phosphate levels in additional subsets of hearts at the end of 30 min of ischemia showed that the adverse effect of angiotensin II on ischemic diastolic function cannot be explained by a greater depletion of myocardial high-energy phosphate compounds since the levels of ATP and CP were similar between hearts treated with angiotensin compared with no drug. There is evidence that ATP produced by anaerobic glycolysis, which cannot be distinguished by measurements oftotal myocardial ATP and CP content, may exert a protective effect against diastolic dysfunction during ischemia and hypoxia (6, 38) . This metabolic pathway cannot explain the adverse effect of angiotensin II on diastolic function because glycolytic ATP generation as reported by myocardial lactate production was not depressed relative to control hearts.
Significance of angiotensin and ischemic dysfunction.
These observations ofthe deleterious effect ofangiotensin II on ischemic diastolic function are consistent with other studies which have examined the potential protection of ACE inhibitors during experimental ischemia (18) (19) (20) . In comparison with our red-cell perfused model of low-flow ischemia, Li and Chen (20) studied the effects of enalapril administration in rats 1 h before sacrifice of the animal and the subsequent imposition of global no-flow ischemia and reperfusion in an isolated buffer-perfused heart model. They observed that hearts from rats which were treated with ACE inhibition demonstrated improved reactive coronary flow associated with improved contractile force during reperfusion. This is consistent with our observation (protocol I) in red cell-perfused hearts subjected to low-flow ischemia that angiotensin II directly promoted vasoconstriction during low-flow ischemia in association with greater depression of systolic and diastolic function during (39) , and that this effect is especially prominent in patients with ischemic heart disease during the stress of exercise (40) . Further clinical studies employing intracoronary administration of ACE inhibitors will be needed to demonstrate a protective effect of ACE inhibitors on ischemic diastolic dysfunction and to distinguish effects of systemic angiotensin II from local cardiac activation. Potential mechanisms. There are several potential mechanisms which could be responsible for the adverse effect ofangiotensin II on diastolic function during low-flow ischemia and subsequent reperfusion. In this isolated heart model, it is unlikely that the effects ofangiotensin II were mediated by facilitation of sympathetic neurotransmitter release (41) . However, a limitation of this study is that this indirect effect ofangiotensin II may be more dominant in vivo.
The subcellular mechanisms of angiotensin II signal transduction are incompletely understood. There is recent evidence that the effects of angiotensin II on cardiac performance and growth may be dependent on receptor-mediated activation of phosphoinositide second messengers and changes in the mobilization and reuptake of cytosolic Ca2" (31, 37, (42) (43) (44) n nI intracellular free Ca2" (7, 8) , the activation of inositol triphosphate and protein kinase C may exacerbate dysfunctional Ca2" homeostasis, and further impair myocardial relaxation. In addition, there is evidence that angiotensin II may promote intracellular alkalinization by enhanced Na' -H' exchange secondary to protein kinase C activation (31, (46) (47) (48) . Preliminary studies from our laboratories using isolated rabbit hearts and rabbit myocytes loaded with the Ca2" indicator Indo-I AM support the notion that the effects ofangiotensin II on contractility may be predominantly mediated by a alkalosis-induced increase in myofilament Ca2" sensitivity rather than a predominant increase in free activator Ca2" (49) . During energy depletion, intracellular acidosis protects against the development of calcium-activated force and diastolic dysfunction (28, 50, 51) . Thus, future studies will need to be done to test the hypothesis that the adverse effect of angiotensin II on diastolic function during ischemia is mediated by intracellular alkalosis and an increased myofilament Ca2" sensitivity. The greater left ventricular systolic pressure in the angiotensin II group at baseline is consistent with an increase in cytosolic Ca2+ or a change in sensitivity to Ca2+.
Clinical implications. These experiments raise the possibility that angiotensin II may play a contributory role in the development ofcongestive heart failure secondary to acute diastolic dysfunction during transient ischemia in patients. In such patients, an increase in angiotensin II via the systemic renin-angiotensin system or via local ACE-specific or nonspecific cardiac angiotensin II-forming pathways (51) could promote adverse changes in both coronary vasomotor tone and diastolic relaxation. The adverse effects of angiotensin II during ischemia may be particularly prominent in the setting of cardiac hypertrophy, in which the cardiac activation of angiotensin II appears to be enhanced (16) . Such hypertrophy and local activation of angiotensin II may occur in a regional distribution in postinfarction remodeling associated with coronary artery disease (52) in addition to the global hypertrophy that occurs in response to pressure overload. Thus, many patients may be predisposed to develop ischemic diastolic dysfunction, mediated at least in part by the actions of the renin-angiotensin system on the heart.
